Eichacker, Peter Q., M.D.
individual record
Senior Investigator
Positions:
- Senior Investigator, Critical Care Medicine Department
Research Areas:
Food Science & Technology,
General & Internal Medicine,
Endocrinology & Metabolism,
Anesthesiology,
Biochemistry & Molecular Biology,
Cardiovascular System & Cardiology,
Pharmacology & Pharmacy,
Infectious Diseases,
Respiratory System,
Microbiology,
Physiology,
Immunology,
Toxicology
Research Areas:
overview
Dr. Eichacker is a Senior Investigator and Head of the Critical Care Medicine Section in the NIH Clinical Center's Critical Care Medicine Department (CCMD). He earned his undergraduate degree from Boston University and his medical degree from New York University. After he completed a residency and chief residency in internal medicine, he had a fellowship in pulmonary medicine at Bronx Municipal Hospital Center and Hospital of the Albert Einstein College of Medicine in New York. He joined NIH in 1986 as a CCMD fellow. In 1990 he was appointed Senior Investigator and Head of the Critical Care Medicine section in CCMD.
selected publications
Academic Articles147
- (2020). Inhibitory Immune Checkpoint Molecule Expression in Clinical Sepsis Studies: A Systematic Review. CRITICAL CARE MEDICINE. 48(9), 1365-1374.
- (2020). Sepsis Bundles That Focus on Clinician Judgment and Proven Interventions Are Needed to Increase Bundle Compliance and Effectiveness. CRITICAL CARE MEDICINE. 48(4), 602-605.
- (2020). The Effects of Obesity on Outcome in Preclinical Animal Models of Infection and Sepsis: A Systematic Review and Meta-Analysis. Journal of Obesity. 2020,
- (2020). Checkpoint inhibitor therapy in preclinical sepsis models: a systematic review and meta-analysis. Intensive Care Medicine Experimental. 8(1),
- (2020). Driving blind: instituting SEP-1 without high quality outcomes data. Journal of Thoracic Disease. 12, S22-S36.
- (2019). Bacillus anthracis lethal toxin, but not edema toxin, increases pulmonary artery pressure and permeability in isolated perfused rat lungs. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY. 316(5), H1076-H1090.
- (2019). Does Obesity Protect Against Death in Sepsis? A Retrospective Cohort Study of 55,038 Adult Patients. CRITICAL CARE MEDICINE. 47(5), 643-650.
- (2018). Evidence Underpinning the Centers for Medicare & Medicaid Services' Severe Sepsis and Septic Shock Management Bundle (SEP-1) A Systematic Review. ANNALS OF INTERNAL MEDICINE. 168(8), 558-+.
- (2018). Evidence Underpinning the Centers for Medicare & Medicaid Services' Severe Sepsis and Septic Shock Management Bundle (SEP-1) RESPONSE. ANNALS OF INTERNAL MEDICINE. 168(8), 610-612.
- (2018). Risks of restrictive red blood cell transfusion strategies in patients with cardiovascular disease (CVD): a meta-analysis. TRANSFUSION MEDICINE. 28(5), 335-345.
- (2017). Analysis of Anthrax Immune Globulin Intravenous with Antimicrobial Treatment in Injection Drug Users, Scotland, 2009-2010. EMERGING INFECTIOUS DISEASES. 23(1), 56-65.
- (2017). Anthrax immune globulin improves hemodynamics and survival during B. anthracis toxin-induced shock in canines receiving titrated fluid and vasopressor support. Intensive Care Medicine Experimental. 5,
- (2017). Bacillus anthracis Edema Toxin Increases Fractional Free Water and Sodium Reabsorption in an Isolated Perfused Rat Kidney Model. INFECTION AND IMMUNITY. 85(7),
- (2017). Shock and lethality with anthrax edema toxin in rats are associated with reduced arterial responsiveness to phenylephrine and are reversed with adefovir. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY. 313(5), H946-H958.
- (2016). Nitric oxide production contributes to Bacillus anthracis edema toxin-associated arterial hypotension and lethality: ex vivo and in vivo studies in the rat. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY. 311(3), H781-H793.
- (2015). An overview of investigational toxin-directed therapies for the adjunctive management of Bacillus anthracis infection and sepsis. EXPERT OPINION ON INVESTIGATIONAL DRUGS. 24(7), 851-865.
- (2015). Bacillus anthracis edema but not lethal toxin challenge in rats is associated with depressed myocardial function in hearts isolated and tested in a Langendorff system. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY. 308(12), H1592-H1602.
- (2015). Does Bacillus anthracis Lethal Toxin Directly Depress Myocardial Function? A Review of Clinical Cases and Preclinical Studies. Toxins. 7(12), 5417-5434.
- (2014). Confirmed Bacillus anthracis Infection among Persons Who Inject Drugs, Scotland, 2009-2010. EMERGING INFECTIOUS DISEASES. 20(9), 1452-1463.
- (2014). Hypothalamic-pituitary-adrenal axis in lethal canine Staphylococcus aureus pneumonia. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM. 307(11), E994-E1008.
- (2014). Tidal Volume and Plateau Pressure Use for Acute Lung Injury From 2000 to Present: A Systematic Literature Review. CRITICAL CARE MEDICINE. 42(10), 2278-2289.
- (2013). Antitumor Necrosis Factor Therapy Is Associated With Improved Survival in Clinical Sepsis Trials: A Meta-Analysis. CRITICAL CARE MEDICINE. 41(10), 2419-2429.
- (2013). B. anthracis edema toxin increases cAMP levels and inhibits phenylephrine-stimulated contraction in a rat aortic ring model. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY. 305(2), H238-H250.
- (2013). Bacillus anthracis Cell Wall Peptidoglycan but Not Lethal or Edema Toxins Produces Changes Consistent With Disseminated Intravascular Coagulation in a Rat Model. JOURNAL OF INFECTIOUS DISEASES. 208(6), 978-989.
- (2013). The Surviving Sepsis Campaign's Revised Sepsis Bundles. Current Infectious Disease Reports. 15(5), 385-393.
- (2012). An overview of anthrax infection including the recently identified form of disease in injection drug users. INTENSIVE CARE MEDICINE. 38(7), 1092-1104.
- (2012). Beneficial effects of stress-dose corticosteroid therapy in canines depend on the severity of staphylococcal pneumonia. INTENSIVE CARE MEDICINE. 38(12), 2063-2071.
- (2012). Efficacy of selective mineralocorticoid and glucocorticoid agonists in canine septic shock. CRITICAL CARE MEDICINE. 40(1), 199-207.
- (2012). Protective Antigen Antibody Augments Hemodynamic Support in Anthrax Lethal Toxin Shock in Canines. JOURNAL OF INFECTIOUS DISEASES. 205(5), 818-829.
- (2011). Anthrax Infection. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE. 184(12), 1333-1341.
- (2011). Anthrax edema toxin has cAMP-mediated stimulatory effects and high-dose lethal toxin has depressant effects in an isolated perfused rat heart model. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY. 300(3), H1108-H1118.
- (2011). Eritoran tetrasodium (E5564) treatment for sepsis: review of preclinical and clinical studies. Expert Opinion on Drug Metabolism & Toxicology. 7(4), 479-494.
- (2011). The Potential Contributions of Lethal and Edema Toxins to the Pathogenesis of Anthrax Associated Shock. Toxins. 3(9), 1185-1202.
- (2011). The effect of heparin administration in animal models of sepsis: A prospective study in Escherichia coli-challenged mice and a systematic review and metaregression analysis of published studies. CRITICAL CARE MEDICINE. 39(5), 1104-1112.
- (2011). The evolving experience with therapeutic TNF inhibition in sepsis: considering the potential influence of risk of death. EXPERT OPINION ON INVESTIGATIONAL DRUGS. 20(11), 1555-1564.
- (2011). The individual survival benefits of tumor necrosis factor soluble receptor and fluid administration are not additive in a rat sepsis model. INTENSIVE CARE MEDICINE. 37(10), 1688-1695.
- (2010). Anthrax Lethal and Edema Toxins Produce Different Patterns of Cardiovascular and Renal Dysfunction and Synergistically Decrease Survival in Canines. JOURNAL OF INFECTIOUS DISEASES. 202(12), 1885-1896.
- (2010). Bacillus anthracis cell wall produces injurious inflammation but paradoxically decreases the lethality of anthrax lethal toxin in a rat model. INTENSIVE CARE MEDICINE. 36(1), 148-156.
- (2010). Bundled care for septic shock: An analysis of clinical trials. CRITICAL CARE MEDICINE. 38(2), 668-678.
- (2010). Evaluating guidelines for critical care: a need for detail. INTENSIVE CARE MEDICINE. 36(10), 1631-1632.
- (2010). Practice Misalignments in Randomized Controlled Trials: Identification, Impact, and Potential Solutions. ANESTHESIA AND ANALGESIA. 111(2), 444-450.
- (2010). Risk of death and the efficacy of eritoran tetrasodium (E5564): Design considerations for clinical trials of anti-inflammatory agents in sepsis. CRITICAL CARE MEDICINE. 38(1), 306-308.
Research Areas:
Food Science & Technology,
General & Internal Medicine,
Endocrinology & Metabolism,
Anesthesiology,
Biochemistry & Molecular Biology,
Cardiovascular System & Cardiology,
Pharmacology & Pharmacy,
Infectious Diseases,
Respiratory System,
Microbiology,
Physiology,
Immunology,
Toxicology
Research Areas: